Lennox-Gastaut Syndrome (LGS) is severe form of epilepsy which often begins in early childhood.  One type of seizure that is common with Lennox-Gastaut Syndrome is a Drop seizure, where the patient temporarily loses all muscle function, loses consciousness and collapses.  It is not uncommon for those suffering from Drop Seizures to experience multiple episodes per week.  Cannabidiol, or CBD, has demonstrated, in studies, to have antiepileptic properties and has had widespread success as a treatment therapy for various types of seizure disorders.

In a collaborative study involving 30 clinics, 225 people with Lennox-Gastaut syndrome participated in a double-blind study to evaluate the safety and efficacy of adding cannabidiol to their current conventional antiepileptic medication.  Patients ranged in age from 2 to 55 years old and were experiencing two or more drop seizures per week. 76 patients received 20mg of CBD, 73 patients received 10mg CBD and the remaining 76 received an equal volume of a placebo substance, each daily, for 14 weeks.  The results showed a definite decrease in drop seizures for those patients receiving CBD: a 41.9% decrease for the group receiving 20mg cannabidiol per day and a 37.2% decrease for the group receiving 10mg cannabidiol per day.  Compared to the placebo group, whose reduction was 17.2%, the study demonstrated a significant reduction in the number of drop seizures for those receiving CBD, in addition to, their current antiepileptic medications.

We are excited to review ongoing research which demonstrates the positive effects of cannabidiol on varying disorders and medical conditions.  To read more about the study mentioned above, please see here.